Navigating Market Volatility: Why Axis Securities is Bullish on Glenmark Pharma, Max Healthcare, and Valor Estate

The Indian stock markets experienced a significant downturn on Friday, mirroring global anxieties fueled by escalating geopolitical tensions and a steady exodus of foreign capital. The air was thick with risk aversion following Israel's military strike on Iran, sending ripples of concern across financial centers worldwide. The BSE Sensex closed down 573.38 points, or 0.70%, settling at 81,118.60, while the NSE's Nifty50 wasn't far behind, plunging 169.60 points, or 0.68%, to finish the day at 24,718.60.

Despite the broader market's cautious stance, certain stocks are poised to capture the attention of astute traders as we head into the new trading week. Among these are Glenmark Pharmaceuticals Ltd, Valor Estate Ltd (formerly DB Realty Ltd), and Max Healthcare Institute Ltd. Our team has delved into the insights provided by analysts at Axis Securities, who have some compelling reasons to be optimistic about these particular scrips.

Valor Estate: Building Momentum for a New Horizon

Recommendation: Buy | Target Price: Rs 266-275 | Stop Loss: Rs 208

Valor Estate, previously known as DB Realty, has truly turned a corner. On the weekly chart, the stock has decisively broken out above a critical resistance zone near Rs 235, confirmed by a powerful bullish candle. This isn't just a fleeting moment; it signals the commencement of a promising medium-term uptrend. What makes this breakout even more convincing is the accompanying surge in trading volumes, indicating robust participation from investors – a sure sign of conviction.

Furthermore, a weekly close above the upper Bollinger Band has ignited a fresh technical "buy" signal, pointing to an underlying strengthening of bullish sentiment. Both the daily and weekly Relative Strength Index (RSI) are comfortably holding above their respective reference lines, reinforcing this positive outlook. Based on this comprehensive analysis, Valor Estate appears to be gearing up for an upward journey, with an estimated upside potential towards the Rs 266-275 levels.

Glenmark Pharmaceuticals: A Healthy Prescription for Growth

Recommendation: Buy | Target Price: Rs 1,817-1,875 | Stop Loss: Rs 1,535

Glenmark Pharmaceuticals is showing robust signs of recovery and growth. In the first week of June 2025, the stock successfully broke out above a falling channel, comfortably surpassing the Rs 1,510 mark with a strong bullish candle on its weekly chart. This week, we've observed the stock forming a higher high-low pattern on the weekly chart, a clear indication that the post-breakout rally is set to continue.

Adding further weight to the bullish argument, Glenmark is currently trading above its key short and medium-term moving averages (20, 50, 100, and 200-day Simple Moving Averages). This alignment strongly suggests a dominant underlying bullish bias. Momentum indicators also lend their support to this positive view: the weekly RSI has not only crossed above the 50 mark but is also sustaining above its reference line, signaling growing bullish momentum. All signs point to a potential upside for Glenmark Pharmaceuticals towards the Rs 1,817-1,875 levels.

Max Healthcare Institute: A Strong Pulse for Future Gains

Recommendation: Buy | Target Price: Rs 1,355-1,400 | Stop Loss: Rs 1,122

Max Healthcare has demonstrated remarkable strength, breaking out strongly from its consolidation range of Rs 1,211–942 on the weekly charts. This breakout, confirmed by a robust bullish candle, signals the continuation of its medium-term uptrend. The stock is consistently forming a higher high–higher low structure and is trading above its upward-sloping trendline, reinforcing a positive bias that investors will find reassuring.

Momentum indicators wholeheartedly support this breakout. The weekly RSI has crossed above its signal line, triggering a fresh "buy" signal. Notably, the RSI has also broken out above an inverted Head & Shoulders pattern, further validating the bullish price action and significantly strengthening overall market sentiment. Based on these compelling technical signals, Max Healthcare appears to be well-positioned for an upside potential towards the Rs 1,355-1,400 levels.